Summary of GlucoTrack Conference Call Company Overview - **Company**: GlucoTrack (NasdaqCM: GCTK) - **Industry**: Continuous Glucose Monitoring (CGM) Core Points and Arguments 1. **Product Development**: GlucoTrack is developing a fully implantable continuous blood glucose monitor that lasts for three years, eliminating the need for wearable devices [2][23] 2. **Market Size**: The CGM market reached $11.6 billion in revenues last year and is still growing at double-digit rates, with only about 50% penetration in the U.S. market [3][15] 3. **Clinical Trials**: GlucoTrack has completed a first-in-human study outside the U.S. and is starting another study in Australia, with plans for a U.S. Investigational Device Exemption (IDE) study [4][27] 4. **Team Expertise**: The company boasts a seasoned team with experience in continuous glucose sensing, cardiovascular, and implantable devices [5] 5. **Market Challenges**: Despite broad reimbursement, there are challenges in increasing CGM adoption due to the discomfort and management issues associated with current wearable devices [3][19] 6. **Unique Value Proposition**: The implantable device offers a "set it and forget it" solution, providing continuous glucose monitoring without the need for on-body wearables [2][23] 7. **Target Population**: The serviceable market is estimated to be around 3 million patients, with a total addressable market of 10.7 million patients needing insulin or at severe hypoglycemic risk [25][32] 8. **Regulatory Pathway**: The company is targeting FDA approval by the end of the year and plans to launch a pivotal trial by 2027 [4][27] Additional Important Information 1. **Patient Feedback**: Surveys indicate that patients desire improvements in CGM technology, particularly regarding the wearability and management of current devices [20][21] 2. **Technological Approach**: The device leverages established cardiovascular technologies to minimize risks associated with new materials and procedures [22][34] 3. **Financial Projections**: The estimated capital required for clinical trials and regulatory approval is projected to be between $20 million to $25 million annually, totaling around $60 million to $75 million for commercial approval [33][34] 4. **Market Penetration**: Current CGM products have a penetration rate of about 30% among the target population, indicating significant room for growth [25][32] This summary encapsulates the key points discussed during the GlucoTrack conference call, highlighting the company's innovative approach to diabetes management and the potential market opportunities ahead.

周五，GlucoTrack(GCTK.US)飙升超123%，报10.91美元。消息面上，GlucoTrack于2025年9月11日宣布 与第六区资本达成协议，出售最高2000万美元普通股。GlucoTrack主营业务为开发植入式连续血糖监测 设备，该设备直接测量血液血糖，消除滞后时间，适用于糖尿病患者。 ...

智通财经APP获悉，周五，GlucoTrack(GCTK.US)飙升超123%，报10.91美元。消息面上，GlucoTrack于 2025年9月11日宣布与第六区资本达成协议，出售最高2000万美元普通股。GlucoTrack主营业务为开发 植入式连续血糖监测设备，该设备直接测量血液血糖，消除滞后时间，适用于糖尿病患者。 ...

At 7:05 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025. Presentation detailsPresenter: Paul V. Goode, PhD, President and Chief Executive Officer ...

For the quarterly period ended June 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or (Address of principal executive offices) (Zip Code) (201) 842-7715 GLUCOTRACK, INC. (Former name, former address and former fiscal year, if changed since last report) (Registrant's telephone ...

Exhibit 99.1 Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash ...

Core Viewpoint - Glucotrack, Inc. is making significant advancements in the development of its fully implantable continuous blood glucose monitor (CBGM) system, with plans to initiate clinical studies in Australia and submit an Investigational Device Exemption (IDE) to the FDA by the end of 2025, while also strengthening its corporate structure and expanding its advisory boards [1][2][11]. Corporate Highlights - The company is on track to implant the first patients in a long-term, multicenter feasibility study of the CBGM system in Australia in Q3 2025 [1]. - An IDE submission to the FDA for the novel CBGM technology is anticipated in Q4 2025 [1]. - The Board of Directors has been strengthened with the appointment of Dr. David S. Hirsh as Medical Director - Cardiology and Dr. Victoria E. Carr-Brendel to the Board [2][5]. - A Patient Advisory Board has been established to incorporate patient perspectives into the development of the CBGM technology [2][5]. Financial Overview - Cash and cash equivalents as of June 30, 2025, were $9.6 million, an increase from $5.6 million as of December 31, 2024, primarily due to $10.7 million in net proceeds from public equity financings [12]. - Research and development expenses for the six months ended June 30, 2025, were $5.0 million, down from $5.7 million in the prior-year period [8]. - Marketing, general, and administrative expenses increased to $3.3 million for the six months ended June 30, 2025, compared to $1.7 million in the prior-year period [9]. - The net loss for the six months ended June 30, 2025, was $11.6 million, compared to a net loss of $7.4 million for the same period in the previous year [10]. Clinical Development - Positive results were reported from a first-in-human study for the CBGM, achieving a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate [11]. - The company received ethical approval in Australia to initiate a long-term clinical study of the CBGM in participants with type 1 and type 2 diabetes [11]. - Glucotrack is participating in the FORGETDIABETES initiative, which aims to develop an artificial pancreas for type 1 diabetes, utilizing the CBGM technology for real-time glucose data [11].

Company Overview - Glucotrack, Inc. is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is developing a long-term implantable continuous blood glucose monitoring system [5][6] Product Details - Glucotrack's Continuous Blood Glucose Monitor (CBGM) is designed to measure blood glucose levels directly from the blood, without the need for on-body wearables, and has a sensor longevity of up to three years [3][6] - The CBGM aims to minimize daily disruptions for diabetes patients by addressing limitations of traditional continuous glucose monitors (CGM), such as frequent sensor changes and challenges associated with on-body wearables [3] Upcoming Events - Glucotrack will participate in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025, in Phoenix, AZ [1] - The company will showcase its CBGM at Booth 1724 and present a poster on physician perspectives regarding continuous blood glucose monitoring technology [2][3]

RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The repurchase was completed as part of the Company’s capital formation strategy and reflects its continued confidence in its product development of a long-te ...